For how we live.
Every article we have published on Cardiovascular Outcomes, newest first.
In ZEUS, 6,376 people with atherosclerosis, chronic kidney disease and inflammation got the IL-6 antibody ziltivekimab or placebo. It cut inflammatory markers sharply but left major cardiovascular events unchanged.
OPTIMAL-DIABETES randomised 9,476 Brazilians with type 2 diabetes to a systolic target below 120 or below 140 mmHg. The tighter target cut pressure by about 14 mmHg but did not reduce major cardiovascular events.
In the Nordic SWEDEGRAFT trial, the no-touch vein-harvesting technique left the rate of death, heart attack, or repeat procedures at 19.8% versus 20.4% through seven years — a difference indistinguishable from chance.
In EMPACT-MI, the SGLT2 inhibitor missed its primary endpoint: 8.2% of patients had a heart-failure hospitalisation or died versus 9.1% on placebo (hazard ratio 0.90; p=0.21). Boehringer and Lilly funded it.
A supplement approved on 26 August adds SURPASS-CVOT to the prescribing information and rewrites the eye warning so it is addressed to patients with a history of retinopathy rather than to patients with diabetes.